Go to
JCI Insight
A conversation with Griffin Rodgers
Ushma S. Neill
Find articles by
Neill, U.
in:
JCI
|
PubMed
|
Google Scholar
|
Published January 4, 2021 - More info
Published in
Volume 131, Issue 1
on
January 4, 2021
J Clin Invest. 2021;131(1):e145540. https://doi.org/10.1172/JCI145540.
© 2021 American Society for Clinical Investigation
J Clin Invest. 2021;131(1):e145540. https://doi.org/10.1172/JCI145540.
© 2021 American Society for Clinical Investigation
Published January 4, 2021
-
Version history
Excerpt: Beginning in the mid-1980s, Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health, led studies demonstrating the effectiveness of the drug hydroxyurea, the first FDA-approved drug for sickle cell disease. Since then, Rodgers (Figure 1) has worked...
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- JCI This Month subscription
- $135
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $195.
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)